Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
February 22, 2026HypertensionOpen Access

Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Although low-dose triple single-pill combinations show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited.

Does a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone reduce blood pressure more effectively than standard-dose telmisartan monotherapy in patients with essential hypertension?

Population

314 subjects with essential hypertension

Comparison

Telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg vs telmisartan 40 mg

Design

Phase III randomized double-blind trial

Follow-up

8 weeks

Key result

Low-dose telmisartan/amlodipine/chlorthalidone SPC reduced systolic BP by 4.0 mm Hg more than standard-dose telmisartan after 8 weeks, with similar safety.

Authors

JAJeong Cheon AhnSCSi Wan ChoiJAJong Hwa Ahn

Discussion

Loading...

Member takes

Overview

Supports low-dose triple SPC over standard monotherapy for hypertension; confirms superiority of early combination regimens in Phase 3 RCTs.

Key Points

  • This study aims to compare the efficacy and safety of a low-dose combination therapy versus standard-dose monotherapy in patients with essential hypertension.
  • Phase III randomized, double-blind trial
  • 314 participants received either low-dose combination or standard-dose telmisartan
  • 8-week treatment duration with blood pressure monitored
  • Primary endpoint: change in mean sitting systolic blood pressure
  • Combination therapy resulted in a significant reduction in systolic blood pressure by −3.8 mm Hg
  • Establishes noninferiority to standard-dose telmisartan
  • Superiority of combination observed with a reduction of −4.0 mm Hg
  • Both groups showed comparable safety profiles with no serious drug-related events

Structured PICO

Does a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone reduce blood pressure more effectively than standard-dose telmisartan monotherapy in patients with essential hypertension?

P
Population
314 subjects with essential hypertension
I
Intervention
Low-dose single-pill combination of telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg for 8 weeks
C
Comparator
Standard-dose telmisartan 40 mg monotherapy for 8 weeks
O
Outcome
Change in mean sitting systolic blood pressure from baseline to week 8surrogate

A low-dose triple single-pill combination of telmisartan, amlodipine, and chlorthalidone provides superior blood pressure reduction compared to standard-dose telmisartan monotherapy without increasing adverse events.

Cite This Study

Ahn et al. (2026) studied this question. Low-dose telmisartan/amlodipine/chlorthalidone SPC reduced systolic BP by 4.0 mm Hg more than standard-dose telmisartan after 8 weeks, with similar safety.

synapsesocial.com/papers/699a9d3c482488d673cd2fd1https://doi.org/10.1161/hypertensionaha.125.25810
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of low‐dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double‐blind, parallel, phase II trial2022 · 18 citations
  2. 2Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial2023 · 8 citations
  3. 3Single-Pill Combination Therapy of Amlodipine, Telmisartan, and Chlorthalidone in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials2024
  4. 4Low‐Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial2026
  5. 5EFFICACY AND SAFETY OF LOW-DOSE TELMISARTAN/S-AMLODIPINE COMBINATION: INTEGRATED RESULTS FROM TWO KOREAN PHASE III TRIALS2026